Clinical and prognostic value of the initial doubling time of prostate-specific antigen in prostate cancer patients
Vol. 58 No. 6 (2012), Articles
Vol. 58 No. 6 (2012)

Clinical and prognostic value of the initial doubling time of prostate-specific antigen in prostate cancer patients

Articles
https://doi.org/10.37469/0507-3758-2012-58-6-817-820
Published 15.12.2012
Russian Research Center for Radiology and Surgical Technologies
Russian Research Center for Radiology and Surgical Technologies
Russian Research Center for Radiology and Surgical Technologies
##article.numberofdownloads## 27
##article.numberofviews## 98
PDF (Русский)

Keywords

рак предстательной железы
общая выживаемость
время удвоения простат-специфического антигена

How to Cite

, , & . (2012). Clinical and prognostic value of the initial doubling time of prostate-specific antigen in prostate cancer patients. Voprosy Onkologii, 58(6), 817–820. https://doi.org/10.37469/0507-3758-2012-58-6-817-820
ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver

Abstract

Kinetic parameters of prostate-specific antigen (PSA) play a pivotal role in diagnostic and treatment of patients with prostate cancer (PCr). Assessment of PSA doubling time (PSADT) can be used for monitoring of treatment efficacy and predicting the outcomes of disease. The aim of the present paper is to analyze the PSADT in patients with different spread of PCr. Moreover, the initial PSADTs were studied with relation to overall survival. 336 PCr patients were included into the study. PSADT was measured usng two point method. Ill patients had localized PCr (T1-2N0M0), 90 - regional-local PCr (T1-2N0M0) and 136 had generalized PCr (T1-4N1-2M1). Results: Median PSADT in patients with generalized PCr amounted to 2,93 months and was significantly lower as compared to groups of patients with local and regionallocal spread of disease - 15,2 and 13,2 months respectively. Follow-up results revealed the link between PSADT and survival rates: the lower is PSADT, the worse are survival rates.
https://doi.org/10.37469/0507-3758-2012-58-6-817-820
##article.numberofdownloads## 27
##article.numberofviews## 98
PDF (Русский)

References

Габелов А.А., Жаринов Г.М. Зависимость эффективности лучевого лечения больных раком шейки матки от скорости роста опухолей // Мед. радиол. 1981. № 6. С. 35-38.

Гланц С. Медико-биологическая статистика. М.: Практика, 1999. 459 с.

Матвеев Б.П.(Ред.) Клиническая онкоурология. М., 2003.

Жаринов Г.М., Пожарисский К.М., Винокуров В.Л.и др. Некоторые кинетические характеристики рака шейки матки // Вопр. онкол. 2009. Т. 55. С. 196 -200.

Choo R., Klotz L., Deboer G. et al. Wide variation of prostate-specific antigen doubling time of untreated, clinically localized, low-to-intermediate grade, prostate carcinoma // BJU Int. — 2004. — Vol. 94. — P. 295.

D'Amico A.V., Renshaw A.A., Sussman В., Chen M.H. Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy // JAMA — 2005. — Vol. 294. — P. 440.

Daskivich T.J., Meredith M.R., William K.Oh. Prostate specific antigen doubling time calculation: not as easy as 1, 2, 4 // J. Urology. — 2006. — Vol. 176. — P. 1928.

Jermal A., Siegel R., Ward E. et al. Cancer statistics // CA Cancer J. Clin. — 2006. — Vol. 56, P. 106-130.

Luboldt H.-J., Schindler J.F., Rubben H. Age-specific reference ranges for prostate-specific antigen asa marker for prostate cancer // Eur. Urol. — 2007. — Suppl. 5 P. 38-48.

Hanks G.E., Hanlon A.L., Lee W.R. et al. Pretreatment prostate-specific antigen doubling times: clinical utility of this predictor of prostate cancer behavior // Int. J. Radiat. Oncol. Biol. Phys. — 1996. — Vol. 34. — P. 549-553.

Nogueira L., Corradi R., Eastham J.A. Prostatic specific antigen for prostate cancer detection // Int. Braz. J. Urol. — 2009. - Vol. 35(5). — P. 521-529

All the Copyright statements for authors are present in the standart Publishing Agreement (Public Offer) to Publish an Article in an Academic Periodical 'Problems in oncology' ...